Effects of the anti-inflammatory pentoxifylline on psychiatric and neuropsychiatric conditions: exploring various off-label utilities with meta-analyses
Inflammopharmacology · 2025
DOI: 10.1007/s10787-024-01616-7 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Inflammopharmacology, 2025. Verfasst von Ahmed Ramzi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Mansoura University, Mansoura, Egypt. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, Mental Disorders, Pentoxifylline. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cairo University.
Abstract (Originalsprache)
Background
Chronic inflammation has been linked to many psychiatric disorders, and therefore, pertinent anti-inflammatory therapies have been empirically evaluated for management. An enduring example of long-term safety, attainability, and versatility has been pentoxifylline (PTX). PTX is a phosphodiesterase inhibitor that modulates inflammatory mediators and affects most blood components and the blood vessels.
Methods
Major databases were systematically searched to identify randomized controlled trials (RCTs) on PTX in psychiatric and neuropsychiatric disorders until September 25, 2024.
Results
21 RCTs were included. Five studies evaluated clinical depression: four on major depressive disorder (MDD) and one on bipolar patients experiencing treatment-resistant depression. PTX significantly reduced depressive symptoms in MDD in the four double-blind, randomized, placebo-controlled trials, with the three studies combining PTX and SSRIs showing statistically significant improvements in response rates. Ten RCTs on cognitive impairment reported beneficial effects, particularly in vascular dementia. Meta-analyses support its efficacy in reducing depressive symptoms, cognitive decline, asthenia, and inflammatory markers.
Conclusion
Exploring the effects of PTX on psychiatric and neuropsychiatric conditions has provided considerable support for its utility across various disorders, most notably in moderate to severe major depressive disorder (as adjunctive therapy with SSRIs) and cognitive impairment in vascular dementia (as monotherapy). Relevantly, the potential of PTX across a wide range of conditions might prove beneficial in cases of co-occurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Mansoura University, Mansoura, Egypt.
- Faculty of Medicine, Damascus University, Damascus, Syria.
- Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
- Faculty of Medicine, Misr University for Science and Technology, Giza, Egypt.
- , Boston NW Suburbs, USA.
- Faculty of Urban and Regional Planning Cairo University, Giza, Egypt. ramzy_220202@stud.furp.cu.edu.eg.
ORCID-Profile: Ahmed Ramzi, Subhia Maya, Nadeen Balousha, Mufreh Amin, Mostafa Ramzi Shiha
Förderung
- Cairo University
Zitieren
APA
Ramzi, A., Maya, S., Balousha, N., Amin, M., Powell, R. C., & Shiha, M. R. (2025). Effects of the anti-inflammatory pentoxifylline on psychiatric and neuropsychiatric conditions: exploring various off-label utilities with meta-analyses. Inflammopharmacology. https://doi.org/10.1007/s10787-024-01616-7
Vancouver
Ramzi A, Maya S, Balousha N, Amin M, Powell RC, Shiha MR. Effects of the anti-inflammatory pentoxifylline on psychiatric and neuropsychiatric conditions: exploring various off-label utilities with meta-analyses. Inflammopharmacology. 2025. doi:10.1007/s10787-024-01616-7
BibTeX
@article{Ramzi2025,
author = {Ramzi, Ahmed and Maya, Subhia and Balousha, Nadeen and Amin, Mufreh and Powell, Robert Charles and Shiha, Mostafa Ramzi},
title = {Effects of the anti-inflammatory pentoxifylline on psychiatric and neuropsychiatric conditions: exploring various off-label utilities with meta-analyses},
journal = {Inflammopharmacology},
year = {2025},
doi = {10.1007/s10787-024-01616-7}
}
EUVIMED